Literature DB >> 12086558

A critical evaluation of the therapeutic range of indinavir.

Craig R Rayner1, Kirsten J Galbraith, Jennifer L Marriott, Gregory J Duncan.   

Abstract

OBJECTIVE: To provide a summary of the patient population, study characteristics, and important findings of the key studies in the literature evaluating concentration-effect relationships and the therapeutic range for indinavir. DATA SOURCES: Literature search strategy involved using MEDLINE (1966-July 2001) and AIDSLINE (MEDSCAPE) databases (up to July 2001). Reference lists from primary literature and review articles were also examined, and conference abstracts were obtained. STUDY SELECTION: English-language articles were considered suitable for review if the clinical trials in HIV patients reported on concentration-effect relationships and/or pharmacokinetic breakpoints or threshold concentrations. A search of the literature identified 20 peer-reviewed references from 18 separate studies including journal articles and conference abstracts. DATA EXTRACTION: The targeted pharmacokinetic parameters and breakpoint values, the rationale for their selection or method of identification, and other study details and limitations were summarized. DISCUSSION: This article highlights the heterogeneity of studies evaluating the therapeutic range of indinavir and provides a summary of important findings of the key studies in the literature evaluating concentration-effect relationships and therapeutic range. Tables are provided to enable clinicians to make use of currently available information on the therapeutic range of indinavir.
CONCLUSIONS: There is insufficient evidence to recommend a general therapeutic range for indinavir. Future investigations should incorporate both pharmacokinetics and pharmacodynamics in order to define a broadly applicable therapeutic range.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086558     DOI: 10.1345/aph.1A467

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.

Authors:  Frank S Rhame; Sandy L Rawlins; Richard A Petruschke; Tara A Erb; Gregory A Winchell; Helene M Wilson; Jonathan M Edelman; Murray A Abramson
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.

Authors:  Julie Bertrand; Jean-Marc Treluyer; Xavière Panhard; Agnes Tran; Solange Auleley; Elisabeth Rey; Dominique Salmon-Céron; Xavier Duval; France Mentré
Journal:  Eur J Clin Pharmacol       Date:  2009-05-14       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.